This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

KD025

Kadmon Holdings, Inc.

Drug Names(s): KD025

Description: KD025 is an orally bioavailable, potent and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2).

ROCK2 is a central effector of a fundamental signaling pathway which serves to modify cell shape and cell migration in response to a variety of stimuli.


KD025 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug